Mark Caswell

Mark Caswell joined Oxford Biomedica as Site Head of US Operations in July 2023. He has more than 25 years of experience and expertise in the biopharma and CDMO space. Previously, Mark was Vice President, Site Head of leading global CDMO Rentschler Biopharma, where he successfully managed all operations at the company’s US facilities in Massachusetts. Mark has a diverse background in various areas of operations, including serving as Head of Operations at Lonza’s Portsmouth, New Hampshire site and as Director, Global Engineering and Technology at Sanofi Genzyme. Mr. Caswell holds a BS in Nuclear Engineering Technology from Thomas Edison State University. Mark is also a proud veteran of the US Navy.